Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 05, 2022

Survival Outcomes Following Palbociclib Plus Aromatase Inhibitor Therapy in HR+/HER2− Metastatic Breast Cancer

NPJ breast cancer


Additional Info

NPJ breast cancer
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer
NPJ Breast Cancer 2022 Oct 11;8(1)114, HS Rugo, A Brufsky, X Liu, B Li, L McRoy, C Chen, RM Layman, M Cristofanilli, MA Torres, G Curigliano, RS Finn, A DeMichele

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading